AKTX
Akari Therapeutics Plc
$15.44
+2.49%
$23.6M
No data for this timeframe.
Vol
Market Cap$23.6M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders2 funds
Inst. Value$119.00
Inst. Activity1 buys / 0 sells
Insider Activity3B / 0S
Insider Net $$999.34
Reddit Sentiment63° Warm
SEC Reports2
Press Releases6
Recent Activity
Jun 4, 2026
other
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
<p align="center"><em>Discussion highlights growing importance on novel ADC payloads, and Akari’s AS
May 22, 2026
SEC
Akari Therapeutics entered into a securities purchase agreement to raise approximately $5.5 million in gross proceeds th
8-K — Impact 7/10
Apr 16, 2026
SEC
Akari Therapeutics' S-1 registration has become effective, allowing the resale of up to 6.375 million American Depositar
EFFECT — Impact 7/10
Dec 16, 2025
Insider
Neal James R bought 2,473 shares
Director @ $0.00 ($0.00)
Dec 16, 2025
Insider
Neal James R bought 2,473 shares
Director @ $0.4041 ($999.34)
Dec 16, 2025
Insider
Neal James R bought 3,093 shares
Director @ $0.00 ($0.00)
Inst.
BANK OF AMERICA CORP — DOUBLED
410 shares ($118.00)
Inst.
UBS Group AG — NEAR_EXIT
60 shares ($61.00)
Price Targets
$26.78
+78.5% upside
Strong Buy
Current $15.00
Low $26.78
Median $26.78
High $26.78
1 analysts
$26.78
$26.78
Analyst Ratings
3Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 8, 2026 | Maxim Group | DOWNGRADE | Buy → Hold |
| Apr 1, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jan 5, 2026 | Ladenburg Thalmann | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.69 ▲ +50.4% | $-1.39 — $0.00 | 71% YoY | 2 |
| Next Q | $-0.75 ▲ +46.4% | $-1.50 — $0.00 | 0% YoY | 2 |
| Current FY | $-2.88 ▲ +48.5% | $-5.77 — $0.00 | 0% YoY | 2 |
| Next FY | $-2.34 ▲ +61.0% | $-4.68 — $0.00 | 19% YoY | 2 |
Latest Reports
NEUTRAL
Press
4/10
Akari Therapeutics announced CEO participation in a Virtual Investor interview discussing its first ASCO abstract accept
May 28, 2026
BEARISH
8-K
7/10
Akari Therapeutics entered into a securities purchase agreement to raise approximately $5.5 million in gross proceeds th
May 22, 2026
BEARISH
EFFECT
7/10
Akari Therapeutics' S-1 registration has become effective, allowing the resale of up to 6.375 million American Depositar
Apr 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BANK OF AMERICA CORP | $118.00 | DOUBLED |
| MORGAN STANLEY | $1.00 | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Dec 16, 2025 | Neal James | BUY | $0.00 |
| Dec 16, 2025 | Neal James | BUY | $999.34 |
| Dec 16, 2025 | Neal James | BUY | $0.00 |
Reddit Sentiment
63°
Warm
Bearish
Neutral
Bullish
2 institutional holders with $119.00 total value (413 shares) as of 2025-Q4. Top holders: BANK, MORGAN. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | 410 | $118.00 | 99.2% | DOUBLED +173.3% |
| 2 | MORGAN STANLEY | 3 | $1.00 | 0.8% | TRIM -50.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 150 | 410 | +173.3% | $118.00 | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 2,154 | 60 | -97.2% | $61.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 17,415 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | TRIM | 6 | 3 | -50.0% | $4.00 | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 18,069 | 23,465 | +29.9% | $28.6K | 2024-Q4 |
| MORGAN STANLEY | TRIM | 8 | 6 | -25.0% | $7.00 | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 33,260 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | ADD | 6 | 8 | +33.3% | $24.00 | 2024-Q3 |
1 unique insiders with 3 transactions. Net insider value: $999.34 ($999.34 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dec 16, 2025 | Neal James R | Director | BUY | 2,473 | $0.00 | $0.00 |
| Dec 16, 2025 | Neal James R | Director | BUY | 2,473 | $0.4041 | $999.34 |
| Dec 16, 2025 | Neal James R | Director | BUY | 3,093 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.
NEUTRAL
4/10
Akari Therapeutics announced CEO participation in a Virtual Investor interview discussing its first
May 28, 2026
BEARISH
6/10
Akari Therapeutics announced a private placement raising approximately $5.5 million through the sale
May 21, 2026
NEUTRAL
4/10
Akari Therapeutics announced the grant of a major European patent (No. 3684773B1) providing broad co
May 12, 2026
BULLISH
6/10
Akari Therapeutics announced a strategic partnership with WuXi XDC to accelerate development of its
Apr 9, 2026
NEUTRAL
4/10
Akari Therapeutics announced a strategic partnership with WuXi XDC to accelerate the development of
Apr 6, 2026
NEUTRAL
4/10
Akari Therapeutics is executing a 1-for-40 reverse split of its ADS ratio, reducing the number of or
Mar 17, 2026
Current analyst consensus: Strong Buy (80% buy). Based on 10 analysts: 3 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$26.78 mean target
+78.5% upside
Strong Buy (3.00)
$26.78 Low
$26.78 High
| Metric | Value |
|---|---|
| Current Price | $15.00 |
| Target Low | $26.78 |
| Target Mean | $26.78 |
| Target Median | $26.78 |
| Target High | $26.78 |
| # Analysts | 1 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.69 | $-1.39 | $0.00 | 71.1% | +50.4% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.75 | $-1.50 | $0.00 | 0.0% | +46.4% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-2.88 | $-5.77 | $0.00 | 0.0% | +48.5% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-2.34 | $-4.68 | $0.00 | 18.9% | +61.0% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.695 | |
| 7d ago | $-0.463 | -0.232 |
| 30d ago | $-1.400 | +0.705 |
| 60d ago | $-1.400 | +0.705 |
| 90d ago | $-1.400 | +0.705 |
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 8, 2026 | Maxim Group | DOWNGRADE | Buy | Hold |
| Apr 1, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | Ladenburg Thalmann | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% | |
| May 1, 2026 | 3 | 5 | 2 | 0 | 0 | 80% | |
| Apr 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
63°
Warm
Bearish
Neutral
Bullish
4 mentions
2 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 24, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Stock Pulse Weekly Recap — May 18–22, 2026
▲ 1
💬 1
⚡ 0.5
Jun 4, 2026
other
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
<p align="center"><em>Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future potentia
May 28, 2026
fda
Akari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor “What This Means” Segment Following ASCO Abstract Acceptance
<p align="center"><em>CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers <
May 22, 2026
short_volume
Short Volume: AKTX — 56.8% short (6.3M / 11.1M)
Short: 6,320,069 | Exempt: 725,501 | TRF Vol: 11,125,940 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 21, 2026
other
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
<p align="center"><em>An ADC with a novel RNA spliceosome modulating payload PH1 paired with a KRAS inhibitor demonstrates synergistic cytotoxic activ
May 21, 2026
activist
Akari Therapeutics Announces $5.5 Million Private Placement Offering
<p align="justify">TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology compan
May 18, 2026
routine
Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase
<p align="center"><em>Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026 </em></p>
May 12, 2026
fda
Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets
Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications <pr
May 12, 2026
earnings_calendar
AKTX Q1 2026 Earnings Scheduled — 2026-05-12
Apr 27, 2026
other
Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload
<p align="center"><br><em>Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) ta
Apr 20, 2026
other
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
<p align="center"><em>Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models</em></p>
Apr 9, 2026
contract
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
<p align="center"><em>CEO Abizer Gaslightwala discusses the Company’s strategic partnership with WuXi XDC and its implications for platform validation
Apr 6, 2026
contract
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026 <pre>Strategic Partnership Enables Akari to Accelerate IND Filing By Late 20
Mar 18, 2026
routine
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
<p align="justify">TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology comp
Mar 17, 2026
activist
Akari Therapeutics Announces ADS Ratio Change
<p align="justify">TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology comp
Mar 13, 2026
other
Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
<p align="center"><em>Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion o